You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME

What Is the Consensus on Novel Nonsteroidal Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease Management in Patients With Type 2 Diabetes? 

  • Authors: George L. Bakris, MD; Pamela R. Kushner, MD, FAAFP; Peter Rossing, MD
  • CME Released: 12/5/2022
  • Valid for credit through: 12/5/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for a global audience of primary care physicians, nephrologists, and diabetologists/endocrinologists.

The goal of this activity is for learners to be better able to improve their awareness of the serious health risks associated with CKD in patients with type 2 diabetes (T2D) and the availability of novel treatment options shown to reduce the risk of associated complications.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mandate for managing patients with T2D
    • Clinical benefits of novel selective nonselective mineralocorticoid receptor antagonists (MRAs)
    • Safety aspects of novel selective nonsteroidal MRAs


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

-

Disclosures for additional planners can be found here.


Faculty

  • George L. Bakris, MD

    Professor of Medicine
    Director, American Heart Association Comprehensive Hypertension Center
    University of Chicago Medicine
    Chicago, Illinois, United States

    Disclosures

    George L. Bakris, MD, has the following relevant financial relationships:
    Consultant or advisor for: Alnylam; AstraZeneca; Bayer; Dia Medica Therapeutics; Horizon; Ionis; KBP Biosciences; Merck; Novo Nordisk; Quantum Genomics
    Research funding from: Bayer

  • Pamela R. Kushner, MD, FAAFP

    Clinical Professor of Medicine
    University of California Irvine Medical Center
    Irvine, California, United States

    Disclosures

    Pamela R. Kushner, MD, FAAFP, has the following relevant financial relationships:
    Consultant or advisor for: Abbott Diabetes Care; AstraZeneca; Bayer; GlaxoSmithKline; Immuvent (former); Intuity (former); Janssen; Lilly/Boehringer Ingelheim; Novo Nordisk (former); Phathom (former); RevHealth (former)
    Speaker or member of speakers bureau for: AstraZeneca; Bayer; GlaxoSmithKline; Janssen; Lilly/Boehringer Ingelheim; Novo Nordisk (former)
    Owns stock (publicly traded) in: Abbott

  • Peter Rossing, MD

    Head of Complications Research
    Steno Diabetes Center Copenhagen
    Herlev, Denmark
    Professor, Department of Clinical Medicine
    University of Copenhagen
    Copenhagen, Denmark

    Disclosures

    Peter Rossing, MD, has the following relevant financial relationships:
    Consultant or advisor for: Abbott; Astellas; AstraZeneca; Bayer; Boehringer Ingelheim; Gilead Sciences; Eli Lilly; Novo Nordisk; Sanofi
    Speaker or member of speakers bureau for: Astellas; AstraZeneca; Bayer; Boehringer Ingelheim; Merck; Novo Nordisk
    Research funding from: AstraZeneca; Bayer; Novo Nordisk

Editor

  • Rita Moreira Da Silva, PhD, MA, PharmD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Rita Moreira Da Silva, PhD, MA, PharmD, has no relevant financial relationships.

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

What Is the Consensus on Novel Nonsteroidal Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease Management in Patients With Type 2 Diabetes? 

Authors: George L. Bakris, MD; Pamela R. Kushner, MD, FAAFP; Peter Rossing, MDFaculty and Disclosures

CME Released: 12/5/2022

Valid for credit through: 12/5/2023

processing....

Transcripción en español

Download the pdf.

 

« Return to: What Is the Consensus on Novel Nonsteroidal Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease Management in Patients With Type 2 Diabetes? 
  • Print